

9<sup>th</sup> ANNUAL ACUTE

# LEUKEMIA MEETING

24<sup>th</sup>-26<sup>th</sup> SEPTEMBER 2020

VIRTUAL MEETING

## COORDINATORS

Dr. Miguel Ángel Sanz  
*Hospital Universitario y Politécnico La Fe, Valencia, España*

Dr. Adolfo de la Fuente  
*MD Anderson Cancer Center Madrid, España*

MD Anderson  
~~Cancer~~ Center  
Madrid • España

#MadridLeukemia

[www.mdanderson.es/cursouleucemia](http://www.mdanderson.es/cursouleucemia)



16:00 - 16:10 **Welcome**

16:10 - 17:25 **SESSION 1 - Diagnostic**

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, Spain  
Dr. Joaquín Sánchez, Hospital Reina Sofia, Córdoba, Spain

16:10 - 16:30 **Major altered signaling pathways in AML**  
Dr. Joaquín Sánchez, Hospital Reina Sofia, Córdoba, Spain

16:30 - 16:50 **MRD assessment and follow up**  
Dr. Konstanze Döhner, Universitätsklinikum Ulm, Germany

16:50 - 17:10 **Impact of coexisting mutations and mechanisms of resistance to new agents**  
Dr. M<sup>a</sup> José Calasanz, CIMA LAB Diagnostics UNAV, Pamplona, Spain

17:10 - 17:25 **Discussion**

17:25 - 17:40 **Break**

17:40 - 19:15 **SESSION 2 - Mieloid malignancies MDS & MF**

Chairs: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

19:40 - 18:00 **Prognostic and management of myelofibrosis patients that fail to conventional treatment**  
Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain

18:00 - 18:20 **Management of lower risk MDS**  
Dr. María Díez Campelo, Hospital Clínico Universitario de Salamanca, Spain

18:20 - 18:40 **CMML management**  
Dr. Breno Gusmão, Hospital Beneficência Portuguesa, São Paulo, Brasil

18:40 - 19:00 **Oral therapies in MDS**  
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA

19:00 - 19:15 **Discussion**

13:30 - 14:05 **SESSION 3 - AML -2**

13:30 - 13:50 **Hope and future**  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

13:50 - 14:05 **Discussion**

14:05 - 15:40 **SESSION 4 - ALL**

Chairs: Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

14:05 - 14:25 **First-line therapy of Ph-positive ALL: current status and perspectives**  
Dr. Sabina Chiaretti, Sapienza University, Rome, Italy

14:25 - 14:45 **Adult LAL: real-life treatment results**  
Dr. Josep M<sup>a</sup> Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain

14:45 - 15:05 **Optimizing 1st line therapy based on MRD in ALL**  
Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA

15:05 - 15:25 **Case based discussion: Introducing Inotuzumab in day to day practice**  
Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

15:25 - 15:40 **Discussion**

15:40 - 15:55 **Break**

15:55 - 17:10 **SESSION 5 - AML -1**

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

15:55 - 16:15 **AML management ELN 2017 update**  
Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany

16:15 - 16:35 **Moving toward targeted approaches in AML**  
Dr. Richard Stone, Dana-Farber Cancer Institute, Boston, USA

16:35 - 16:55 **Update in Bcl2 inhibitors**  
Dr. Daniel Pollyea, University of Colorado School of Medicine, USA

16:55 - 17:10 **Discussion**

17:10 - 17:25 **Break**

17:25 - 19:05 **SESSION 6 - Immunotherapy**

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain  
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

17:25 - 17:45 **Immunotherapy in ALL**  
Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA

17:45 - 18:05 **Harnessing the immune system for threatening AML**  
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

18:05 - 18:25 **CAR T: organization and start-up of a unit**  
Dr. Manuel Guerreiro, Hospital Universitario y Politécnico La Fe. Valencia, Spain

18:25 - 18:45 **CAR-T cell therapy in adult patients with ALL**  
Dr. Nicolas Boissel, Hôpital Saint-Louis, Paris, France

18:45 - 19:05 **Immunotherapy approaches in MDS**  
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA

19:05 - 19:20 **Discussion**

09:30 - 11:05 **SESSION 7 - AML-3**

Chairs: Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

09:30 - 09:50 **First line FLT3 AML**  
Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

09:50 - 10:10 **Study of relapsed LAM**  
Dr. Eva Barragán, Hospital Universitario y Politécnico La Fe, Valencia, Spain

10:10 - 10:30 **Salvage therapy FLT-3**  
Dr. Josefina Serrano, Hospital Universitario Reina Sofia, Córdoba, España

10:30 - 10:50 **The challenge of starting maintenance after transplant**  
Dr. Giovanni Martinelli, University of Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy

10:50 - 11:05 **Discussion**

11:05 - 11:20 **Break**

11:20 - 13:55 **SESSION 8 - AML-4. Session high risk**

Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

11:20 - 11:40 **Accurate diagnosis**  
Dr. Jordi Esteve, Hospital Clinic, Barcelona, Spain

11:40 - 12:00 **Goals not achieved in the Fit patient with AML. Decreasing mortality**  
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain

12:00 - 12:20 **Current status of the transplant indication**  
Dr. Jaime Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

12:20 - 12:40 **New formulations**  
Dr. Raquel Sánchez, MD Anderson Cancer Center Madrid, Spain

12:40 - 13:00 **New ways to deliver induction chemotherapy in AML**  
Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain

13:00 - 13:20 **Houston experience**  
Dr. Guillermo Montalbán Bravo, MD Anderson Cancer Center, Houston, USA

13:20 - 13:40 **French experience of CPX**  
Dr. Thomas Cluzeau, Centre Hospitalier Universitaire de Nice, France

13:40 - 13:55 **Discussion**

13:55 - 14:10 **Break**

14:10 - 15:40 **SESSION 9 - COVID 19**

Chairs: Dr. Josep M<sup>a</sup> Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

14:10 - 14:30 **COVID 19 Session: presentation**  
Dr. Josep M<sup>a</sup> Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain

14:30 - 15:40 **Discussion**  
Dr. Jaime Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain  
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA  
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA  
Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany  
Dr. Breno Gusmão, Hospital Beneficência Portuguesa, São Paulo, Brasil  
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain  
Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

15:40 - 15:50 **Closing**

## SPONSORS

## ORGANIZED BY

**MD Anderson**  
**Cancer Center**  
Fundación • España

### PLATINUM



### GOLD



### SILVER



### COLLABORATOR



## CREDITS

Continuing Education Credits requested to the Spanish National Health System.  
With the collaboration of the Educational Committee of MD Anderson Cancer Center Madrid.

## TECHNICAL SECRETARIAT

**doctaforum**  
MEDICAL MARKETING SPECIALISTS | (+34) 91 372 02 03  
cursoleucemia@doctaforum.com  
www.mdanderson.es/cursoleucemia